Compare JFIN & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | JFIN | BME |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Trusts Except Educational Religious and Charitable |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.5M | 536.7M |
| IPO Year | 2019 | N/A |
| Metric | JFIN | BME |
|---|---|---|
| Price | $7.15 | $41.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 245.8K | 34.0K |
| Earning Date | 11-25-2025 | 01-01-0001 |
| Dividend Yield | ★ 11.22% | 6.26% |
| EPS Growth | ★ 50.48 | N/A |
| EPS | ★ 4.56 | 1.44 |
| Revenue | ★ $918,148,810.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $1.56 | $28.37 |
| Revenue Growth | ★ 8.99 | N/A |
| 52 Week Low | $5.78 | $35.53 |
| 52 Week High | $19.23 | $43.20 |
| Indicator | JFIN | BME |
|---|---|---|
| Relative Strength Index (RSI) | 23.66 | 78.64 |
| Support Level | $6.96 | $39.70 |
| Resistance Level | $8.01 | $40.35 |
| Average True Range (ATR) | 0.54 | 0.47 |
| MACD | -0.10 | 0.14 |
| Stochastic Oscillator | 9.72 | 93.28 |
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.